Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 1
1993 1
1995 4
1996 1
1998 3
1999 1
2001 1
2002 1
2003 7
2004 10
2005 6
2006 10
2007 5
2008 5
2009 3
2010 3
2011 6
2012 1
2013 8
2014 6
2015 3
2016 5
2018 2
2019 1
2020 0
Text availability
Article attribute
Article type
Publication date

Similar Articles for PMID: 21149519

90 results
Results by year
Filters applied: . Clear all
Page 1
New approaches to rewarding pharmaceutical innovation.
Grootendorst P, Hollis A, Levine DK, Pogge T, Edwards AM. Grootendorst P, et al. CMAJ. 2011 Apr 5;183(6):681-5. doi: 10.1503/cmaj.100375. Epub 2010 Dec 13. CMAJ. 2011. PMID: 21149519 Free PMC article. No abstract available.
Limiting "evergreening" for a better balance of drug innovation incentives.
Stanbrook MB. Stanbrook MB. CMAJ. 2013 Aug 6;185(11):939. doi: 10.1503/cmaj.130992. Epub 2013 Jul 22. CMAJ. 2013. PMID: 23877665 Free PMC article. No abstract available.
[New drugs and European procedures of approval. The European Agency for the Evaluation of Medicinal Products' role].
Ainsworth MA. Ainsworth MA. Ugeskr Laeger. 2003 Apr 14;165(16):1648-9. Ugeskr Laeger. 2003. PMID: 12756819 Danish.
Biogenerics standoff.
Herrera S. Herrera S. Nat Biotechnol. 2004 Nov;22(11):1343-6. doi: 10.1038/nbt1104-1343. Nat Biotechnol. 2004. PMID: 15529145 No abstract available.
A critical tipping point.
Zuckerman MB. Zuckerman MB. US News World Rep. 2002 Apr 22;132(13):72. US News World Rep. 2002. PMID: 11993366 No abstract available.
China offers alternative gateway for experimental drugs.
Jia H, Kling J. Jia H, et al. Nat Biotechnol. 2006 Feb;24(2):117-8. doi: 10.1038/nbt0206-117. Nat Biotechnol. 2006. PMID: 16465139 No abstract available.
Balancing US patent and FDA approval processes: strategically optimizing market exclusivity.
Fernandez DS, Huie JT. Fernandez DS, et al. Drug Discov Today. 2004 Jun 15;9(12):509-12. doi: 10.1016/S1359-6446(04)03067-3. Drug Discov Today. 2004. PMID: 15183155 No abstract available.
Expanded Access to Investigational Drugs: What Physicians and the Public Need to Know about FDA and Corporate Processes.
Finkelstein PE. Finkelstein PE. AMA J Ethics. 2015 Dec 1;17(12):1142-6. doi: 10.1001/journalofethics.2015.17.12.stas1-1512. AMA J Ethics. 2015. PMID: 26698587 Free article. No abstract available.
Compulsory licensing to regulated licensing: effects on the conflict between innovation and access in the pharmaceutical industry.
Gillat A. Gillat A. Food Drug Law J. 2003;58(4):711-40. Food Drug Law J. 2003. PMID: 15027457 No abstract available.
Innovative Clinical Trial Designs Lead to New Drug Approvals.
Miller DJ. Miller DJ. ONS Connect. 2016 Mar;31(3):22. ONS Connect. 2016. PMID: 27044204 No abstract available.
90 results
Jump to page
Feedback